J9330 Temsirolimus injection
Also known as: temsirolimus, Torisel
Injection of temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor. Used for renal cell carcinoma and lymphoma.
In Plain Language
kidney cancer injection; immunosuppressive cancer drug
Clinical Context
First-line therapy for advanced renal cell carcinoma. Also used for relapsed/refractory mantle cell lymphoma.
RVU Information
CPT J9330 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9330?
CPT J9330 (Temsirolimus injection) is a J Codes (Drugs) code. Injection of temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor. Used for renal cell carcinoma and lymphoma.
How is J9330 administered?
CPT J9330 is administered by a healthcare provider, typically via injection or infusion. First-line therapy for advanced renal cell carcinoma. Also used for relapsed/refractory mantle cell lymphoma. It is used by Oncology, Urology, Hematology.
When is CPT J9330 used?
First-line therapy for advanced renal cell carcinoma. Also used for relapsed/refractory mantle cell lymphoma.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.